BRIM closes a $45.8 million rights issue early to accelerate its pipeline of regenerative peptides
Taipei, Taiwan, 13th September 2023 / Sciad Newswire / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint diseases, announced today that 22,500 shares have been issued at...
Source: pharmiweb.com